Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Applied StemCell Licenses Its TARGATT™ CHO Cell Technology for Biotherapeutics Development
Applied StemCell Licenses Its TARGATT™ CHO Cell Technology to Twist Bioscience Corp. for Biotherapeutics Development
Milpitas, California, January 19th, 2021 — The multi-platform gene-editing company, Applied StemCell (ASC), announced a commercial license of its TARGATT™ CHO technology to Twist Bioscience (Twist), a global innovative synthetic biology company. Execution of the license agreement was based on the evaluation result of the TARGATT™ CHO cell platform by Twist to assess its suitability for Twist’s antibody discovery, library screening, and bioproduction process. [Read more…]
Results from phase 3 gene therapy trial for painful diabetic peripheral neuropathy has been published online by Clinical and Translational Science
Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.
-
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.
[Read more…]
JOP POST: Chief Manufacturing & Development Officer at Exopharm
Job Title: Chief Manufacturing & Development Officer
Company: Exopharm
- Exosome therapeutic bioproducts
- World leader and innovator
- Listed company based in Melbourne Australia
- Lead the 20 person innovation and development team in this expanding biotech
Established in 2013 and listed in 2018, Exopharm (ASX:EX1) was founded on the conviction that exosomes/EVs will become a new class of medicines to treat a many medical conditions. [Read more…]
Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix
-
JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.
-
The hydrogel kit is easy to use (with Buffer and Crosslinker).
-
JellaGel™ can be used at room temperature.
Jellagen® Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels allow cells to grow and interact with all of their surroundings which makes a huge difference. [Read more…]
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 144
- Next Page »